×
More Charts Below
Aceragen Total Liabilities 2010-2023 | ACGN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Recent Trends
Aceragen total liabilities from 2010 to 2023. Total liabilities can be defined as the total value of all possible claims against the corporation.
Aceragen Total Liabilities 2010-2023 | ACGN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Aceragen total liabilities from 2010 to 2023. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$209.6B
Amgen (AMGN)
$149.1B
Gilead Sciences (GILD)
$130.2B
Vertex Pharmaceuticals (VRTX)
$125.6B
Bristol Myers Squibb (BMY)
$100.2B
CSL (CSLLY)
$74.3B
GSK (GSK)
$74.1B
Regeneron Pharmaceuticals (REGN)
$61.6B
Argenex SE (ARGX)
$36.2B
Alnylam Pharmaceuticals (ALNY)
$30.5B
BioNTech SE (BNTX)
$23.7B
BeiGene (ONC)
$22.8B
Biogen (BIIB)
$17.4B
Genmab (GMAB)
$13.3B
Genmab (GNMSF)
$13.3B
Insmed (INSM)
$13.2B
BioMarin Pharmaceutical (BMRN)
$11.3B
Illumina (ILMN)
$11.3B
Incyte (INCY)
$11.3B
Ascendis Pharma (ASND)
$10.1B
Exelixis (EXEL)
$10B
Swedish Orphan Biovitrum (BIOVF)
$9.6B
Moderna (MRNA)
$9.6B
QIAGEN (QGEN)
$9B
Exact Sciences (EXAS)
$7.7B
Bio-Techne Corp (TECH)
$7.6B
Repligen (RGEN)
$7.3B
Halozyme Therapeutics (HALO)
$7.3B
Roivant Sciences (ROIV)
$7.2B
Revolution Medicines (RVMD)
$6.8B